Scarica l'app Stockscreener
1.84
6.12%
-0.12
Pre-mercato:
1.92
0.08
+4.35%
Precedente Chiudi:
$1.96
Aprire:
$1.87
Volume 24 ore:
16,224
Relative Volume:
0.07
Capitalizzazione di mercato:
$5.14M
Reddito:
-
Utile/perdita netta:
$-14.11M
Rapporto P/E:
-0.1717
EPS:
-10.7181
Flusso di cassa netto:
$-13.60M
1 W Prestazione:
-2.13%
1M Prestazione:
-11.54%
6M Prestazione:
-20.69%
1 anno Prestazione:
-61.94%
Intervallo 1D:
$1.84
$1.9437
Intervallo di 1 settimana:
$1.84
$1.99
Portata 52W:
$1.6701
$14.24
Processa Pharmaceuticals Inc Stock (PCSA) Company Profile
Nome
Processa Pharmaceuticals Inc
Settore
Industria
Telefono
443-776-3133
Indirizzo
601 21ST STREET, SUITE 300, VERO BEACH
Compare PCSA vs VRTX, REGN, MRNA, ARGX, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PCSA
Processa Pharmaceuticals Inc
|
1.84 | 5.81M | 0 | -14.11M | -13.60M | -10.72 |
VRTX
Vertex Pharmaceuticals Inc
|
510.72 | 130.64B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
798.17 | 80.46B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
172.94 | 57.48B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
988.20 | 61.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
365.67 | 39.20B | 5.76B | 514.49M | 1.10B | 4.4813 |
Processa Pharmaceuticals Inc Stock (PCSA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-04-25 | Iniziato | H.C. Wainwright | Buy |
Processa Pharmaceuticals Inc Borsa (PCSA) Ultime notizie
Processa Pharmaceuticals at H.C. Wainwright: bets on vt-7208 By Investing.com - Investing.com South Africa
Processa Pharmaceuticals at wells fargo healthcare conference: cash fuels vt-7208 push - Investing.com Canada
Processa Pharmaceuticals Inc. (PCSA) Peer Comparison – Compare with Others - Value Research
Processa Pharmaceuticals Inc. (PCSA) Key Financial Ratios – Valuation, Profitability & More - Value Research
Processa Pharmaceuticals Inc. (PCSA) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
A doctor on Processa Pharmaceuticals' board will present at two investor conferences on Sept. 10 and 11. - Stock Titan
Processa Pharmaceuticals to Participate in Upcoming Investor Conferences - Yahoo Finance
Processa Pharmaceuticals Inc. (PCSA) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Processa (PCSA) Range: Closes 0.47% Lower at $2.14 in Latest Trading; Next Test: Support at $2.03 and Resistance at $2.25 Frame the RangeDark Pool Volume - vinanet.vn
Processa Pharmaceuticals (NASDAQ: PCSA) gains new 5.8% owner with no sole control - Stock Titan
Processa Pharmaceuticals (PCSA) Slips 12% as Biotech Volatility PersistsChaikin Flow - dars.gov.et
Processa Pharmaceuticals 3Q 2026: Net loss $(3.27M), EPS $(1.19) — 10-Q Summary - TradingView
Processa Pharmaceuticals (NASDAQ: PCSA) lands $183M funding and Vidya BTK acquisition - Stock Titan
Processa Pharmaceuticals shareholders approve incentive plan amendment at annual meeting - Investing.com Nigeria
Form 8K Processa Pharmaceuticals Inc For: 14 August By Investing.com - Investing.com Nigeria
Processa Pharmaceuticals (PCSA) Slips 2.34% to $2.5 as Support at $2.38 Comes into FocusPercent Above MA - vinanet.vn
Processa Pharmaceuticals Inc (PCSA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Processa Pharmaceuticals shareholders approve incentive plan amendment and board elections - Investing.com UK
Form 8K Processa Pharmaceuticals Inc For: 11 August By Investing.com - Investing.com Nigeria
Processa Pharmaceuticals (PCSA) Surges 11.74% to $2.57 — Poised for a Test of $2.70 ResistanceQuality Factor - vinanet.vn
Processa Pharmaceuticals Inc (NASDAQ: PCSA) Share Price, PCSA Stock News, PCSA Share Price & Updates - Kalkine
Processa Pharmaceuticals Inc (PCSA) Stock News Today - TradingKey
Processa Pharmaceuticals Inc (PCSA) Earnings, Actual EPS, EPS Estimates & Results - stocktwits.com
Processa Pharmaceuticals, Inc. 8-K SEC Filing Details – Nasdaq Listed Company Information (July 30, 2026) - Minichart
Processa Pharmaceuticals Shareholders Approve Key Governance Changes - TipRanks
Processa Pharmaceuticals (NASDAQ: PCSA) adds 200,000 incentive shares - Stock Titan
Mintz Advises on $200 Million Private Placement Concurrent with Vidya Therapeutics’ and Processa Pharmaceuticals’ Merger Transaction - Mintz
Form 4 Processa Pharmaceuticals Inc For: 30 July By Investing.com - Investing.com Nigeria
Processa acquires Vidya and its BTK inhibitor - The Pharma Letter
Processa Pharmaceuticals, Inc. announced that it expects to receive $200 million in funding from a group of investors - marketscreener.com
Processa Merges With Vidya and Secures $200 Million PIPE; Terminates Elion License - TradingView
PROCESSA PHARMACEUTICALS, INC. ANNOUNCES ACQUISITION OF VIDYA THERAPEUTICS, INC. AND APPROXIMATELY $200 MILLION CONCURRENT PRIVATE PLACEMENT TO ADVANCE BTK INHIBITOR, VT-7208, IN MULTIPLE DISEASE AREA - GlobeNewswire
PCSA: Stock-for-stock acquisition and $200M PIPE create a BTK-focused biotech with runway into 2029 - TradingView
Processa Pharmaceuticals Inc - TradingKey
Form 4 Processa Pharmaceuticals Inc For: 28 July By Investing.com - Investing.com Nigeria
Processa Pharmaceuticals (PCSA) grants director 33,500 RSUs and reports option stake - Stock Titan
Processa Pharmaceuticals acquires Vidya, raises strategic funding - TipRanks
Processa Pharmaceuticals Inc (PCSA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Processa Pharmaceuticals Inc (PCSA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
PCSA|Processa Pharmaceuticals Inc|Price:2.080|Chg%:-0.065 - TradingKey
PCSA|Processa Pharmaceuticals Inc|Price:2.605|Chg%:+0.005 - TradingKey
Processa Pharma Market Sentiment - Benzinga España
Processa Pharmaceuticals Inc (PCSA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Processa Pharmaceuticals Inc (PCSA) Income Statement - TradingKey
Processa Pharmaceuticals Inc (PCSA) Balance Sheet - TradingKey
PCSA|Processa Pharmaceuticals Inc|Price:2.050|Chg%:-0.050 - TradingKey
Processa Pharmaceuticals Inc (PCSA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
PCSA Q4 2025 Earnings: Significant EPS Miss Highlights Ongoing Development CostsRevenue Growth Report - vinanet.vn
Processa Pharmaceuticals (PCSA) Shares Rise 3% as Support Holds Above $2.19Triple Bottom - vinanet.vn
PCSA Q4 2025 Earnings: Deeper Loss Per Share Yet Stock Rises 4.2% – Investor Focus Shifts to Pipeline ProgressTax Rate Impact - dars.gov.et
Processa Pharmaceuticals Inc. (PCSA) Q4 2025 Earnings: EPS Misses Estimates, No Revenue ReportedOperating Margin Analysis - dars.gov.et
Processa Pharmaceuticals Inc Azioni (PCSA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Processa Pharmaceuticals Inc Azioni (PCSA) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Lin Patrick | Chief Business - Strategy Off |
Jun 30 '26 |
Buy |
1.93 |
2,106 |
4,065 |
13,113 |
| Ng George K | Chief Executive Officer |
Jul 01 '26 |
Buy |
1.93 |
3,057 |
5,900 |
15,492 |
| SKIBSTED RUSSELL | Chief Financial Officer |
Jun 30 '26 |
Buy |
1.93 |
3,277 |
6,325 |
16,689 |
| Young David | Pres. Research & Development |
Jun 30 '26 |
Buy |
1.93 |
2,531 |
4,885 |
21,729 |
| Young David | Pres. Research & Development |
Jun 15 '26 |
Buy |
2.22 |
2,067 |
4,589 |
19,198 |
| SKIBSTED RUSSELL | Chief Financial Officer |
Jun 15 '26 |
Buy |
2.22 |
2,654 |
5,892 |
13,412 |
| Ng George K | Chief Executive Officer |
Jun 15 '26 |
Buy |
2.22 |
2,465 |
5,472 |
12,435 |
| Lin Patrick | Chief Business - Strategy Off |
Jun 15 '26 |
Buy |
2.22 |
1,831 |
4,065 |
11,007 |
| Guy Wendy | Chief Administrative Officer |
Jun 15 '26 |
Buy |
2.22 |
2,118 |
4,702 |
11,958 |
| Young David | Pres. Research & Development |
May 29 '26 |
Buy |
2.57 |
1,786 |
4,590 |
17,131 |
0.05%
1.96%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):